Status:
TERMINATED
Pregabalin and Orofacial Neuropathic Pain
Lead Sponsor:
University of Toronto
Collaborating Sponsors:
Pfizer
Conditions:
Neuropathic Pain
Orofacial Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether pregabalin can decrease pain and improve quality of life in patients who have nerve pain on the mouth or the face
Detailed Description
Neuropathic pain (NP) is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system. At the trigeminal area where somatosensory nerves are often damaged during dental...
Eligibility Criteria
Inclusion
- Patients 18 years of age or older, males and females
- history of dental and/or maxillofacial treatment/surgery that may cause nerve injury (e.g. root canal treatment, implant placement, deep restorations, tooth extractions, injection of anesthetics)
- patients who score 12 on the validated self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS; Bennett et al. 2005) for extra-oral sites, or 9 for intra-oral sites (the scoring for extra-oral sites is taken as suggested; for intra-oral sites, the 5-point scoring for question 2 has been removed and the score proportionally adjusted, since it is difficult for patients to see color changes in their mouth)
- pain rated 4 or more on a numerical scale (0 being no pain, 10 being the most intense pain imaginable), on a daily basis
- pain lasting more than 6 months
- absence of identifiable organic lesion, inflammation or infection
- normal serum creatinine
- reports that current and previous pain medications failed to provide adequate relief (e.g., analgesic, non-steroidal anti-inflammatories, opioids, antidepressants)
- if currently using medication, acceptance of a wash-out period of at least one week, during which only Tylenol can be used as rescue medication
- able to use the Palm handheld device to report daily pain
Exclusion
- lactating, pregnancy (potentially child bearing patients need to have a referral from family physician stating that the patient is not expecting or to be using contraception)
- renal impairment or renal failure (contra-indication to pregabalin)
- congestive heart failure or liver disease
- currently suffering from trigeminal neuralgia
- history of mental disorder, widespread pain or other severe pain conditions that may confound the pain assessment (e.g. depression, chronic fatigue, migraine headaches, fibromyalgia, severe chronic pain conditions)
- intolerance or allergy to gabapentin and pregabalin
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00852436
Start Date
February 1 2009
End Date
October 1 2010
Last Update
June 3 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. P. Watson's office
Etobicoke, Ontario, Canada, M9V 4B8
2
University of Toronto
Toronto, Ontario, Canada, M5G1G6